RESUMO
Importance: There is a need for improved immunogenicity of hepatitis B virus (HBV) vaccines among young adults with risk of infection. Objectives: To demonstrate manufacturing equivalence of a 3-antigen (3A) HBV vaccine, evaluate noninferiority of seroprotection rate (SPR) of 3A-HBV vs single-antigen (1A) HBV after 2 and 3 vaccine doses, and compare safety and reactogenicity between 3A-HBV and 1A-HBV vaccines. Design, Setting, and Participants: This phase 3, double-blinded, randomized clinical trial included healthy adults aged 18 to 45 years randomized to 1 of three 3A-HBV groups or 1 control group receiving 1A-HBV. The trial was conducted at 37 community clinics and academic hospitals in Canada, Europe, the United Kingdom, and the United States between December 2017 and October 2019. Participants were followed up for 48 weeks after the first vaccination. Interventions: Intramuscular administration of 3A-HBV (10 µg) or 1A-HBV (20 µg) on days 0, 28, and 168. Main Outcomes and Measures: Geometric mean concentration (GMC) of serum hepatitis B surface antibodies (anti-HBs) and proportion of participants achieving seroprotection. Results: Of 2838 participants, 1638 (57.8%) were women, 2595 (91.5%) were White, and 161 (5.7%) were Black or African American. A total of 712 participants (25.1%) were randomized to the 1A-HBV group and 2126 (74.9%) to 3A-HBV. The mean (SD) age at informed consent was 33.5 (8.0) years. The study demonstrated 3A-HBV lot-to-lot consistency, as the 2-sided 95% CIs for each pairwise comparison for the anti-HBs GMC ratios were within 0.67 and 1.50 (eg, adjusted GMC ratio, lot A vs lot B: 0.82; 95% CI, 0.67-1.00; lot A vs lot C: 0.95; 95% CI, 0.78-1.15; lot B vs lot C: 1.16; 95% CI, 0.95-1.41). The SPR of the pooled 3A-HBV was noninferior to 1A-HBV and higher than 1A-HBV after 2 vaccinations at day 168 (90.4% [95% CI, 89.0%-91.8%] vs 51.6% [95% CI, 47.5%-55.6%]) and 3 vaccinations at day 196 (99.3% [95% CI, 98.7%-99.6%] vs 94.8% [95% CI, 92.7%-96.4%]). The mean GMC of anti-HBs with 3A-HBV was 7.9 times higher after 2 vaccinations at day 168 and 3.5 times higher after 3 vaccinations at day 196 compared with 1A-HBV (after 2 vaccinations, 3A-HBV: GMC, 118.7 mIU/mL; 95% CI, 108.0-129.0 mIU/mL; SE, 1.0 mIU/mL; 1A-HBV: GMC, 15.0 mIU/mL; 95% CI, 12.9-17.5 mIU/mL; SE, 1.0 mIU/mL; after 3 vaccinations, 3A-HBV: GMC, 5442.4 mIU/mL; 95% CI, 4967.0-5963.0 mIU/mL; SE, 1.0 mIU/mL; 1A-HBV: 1567.2 mIU/mL; 95% CI, 1338.0-1834.0 mIU/mL; SE, 1.0 mIU/mL). Rates of local and systemic reactogenicities were higher with 3A-HBV compared with 1A-HBV (local: 1805 of 2124 [85.0%] vs 469 of 712 [65.9%]; systemic: 1445 [68.0%] vs 428 [60.1%]). Vaccine discontinuation due to adverse events (AE) was uncommon, and serious AEs were infrequent, reported in 42 participants (2.0%) and 3 participants (0.4%) in the 3A-HBV and 1A-HBV groups, respectively. Conclusions and Relevance: In this study, consistently higher antibody concentrations and SPRs were found with 3A-HBV after 2 and 3 doses vs 1A-HBV in adults aged 18 to 45 years old. The safety and efficacy of 3A-HBV shows its usefulness for the prevention of hepatitis B in young healthy adults. Trial Registration: Clinicaltrials.gov Identifier: NCT03408730; EU Clinical Trials Number: 2017-001820-22.
Assuntos
Anticorpos Anti-Hepatite B/efeitos dos fármacos , Vacinas contra Hepatite B/normas , Imunogenicidade da Vacina/efeitos dos fármacos , Adolescente , Adulto , Método Duplo-Cego , Feminino , Antígenos de Superfície da Hepatite B/efeitos adversos , Antígenos de Superfície da Hepatite B/farmacologia , Antígenos de Superfície da Hepatite B/uso terapêutico , Vacinas contra Hepatite B/imunologia , Vacinas contra Hepatite B/farmacologia , Humanos , Imunogenicidade da Vacina/imunologia , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Burkina Faso is a high endemicity country for HBV infection. However, there are few data on vaccine coverage against HBV. The aim of this study was to contribute to the improvement of HBV vaccine coverage in Ouagadougou through HBV screening. METHODS: Awareness campaigns and voluntary hepatitis B screening were organized in the twelve districts of Ouagadougou by the "SOS Hepatitis Burkina" association. A rapid HBsAg detection test (Abon Biopharma Guangzhou, Co., Ltd. Chine) was performed on 2216 individuals, who voluntarily answered a series of questions. Vaccination against hepatitis B was proposed to HBV negative participants. RESULTS: In a sample of 2216 participants, aged 1 to 78 years (mean age 29.7 ± 14.7 years); a prevalence of 10.4% (230/2216) of HBsAg was obtained. This prevalence was high in the age groups 31 to 40 years (14.5%) and 41 to 50 years (15.0%). The prevalence of HBV was higher in the sixth district (14.3%) of Ouagadougou. At the end of the screening, 1202/1986 HBV negative participants were vaccinated, resulting in a vaccination rate of 60.5%. Vaccination coverage ranged from 44.5 to 73.7% all twelve districts. CONCLUSIONS: This study still reports a high prevalence of HBV infection among young people with a peak in the sixth district of Ouagadougou. The study achieved high vaccination coverage in all age groups and districts of Ouagadougou. TRIAL REGISTRATION: The present study has been approved by the Ethics Committee for Health Research of Burkina Faso. CERS201501006 Registered 14 January 2015.
Assuntos
Vírus da Hepatite B/imunologia , Hepatite B/epidemiologia , Hepatite B/prevenção & controle , Programas de Imunização/estatística & dados numéricos , Vacinação/estatística & dados numéricos , Adolescente , Adulto , Idoso , Burkina Faso/epidemiologia , Criança , Pré-Escolar , Erradicação de Doenças , Feminino , Hepatite B/sangue , Hepatite B/economia , Anticorpos Anti-Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Vacinas contra Hepatite B/normas , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Estudos Soroepidemiológicos , Vacinação/economia , Adulto JovemRESUMO
Before release onto the market, it must be demonstrated that the total and free polysaccharide (poly ribosyl-ribitol-phosphate, PRP) content of Haemophilus influenzae type b (Hib) vaccine complies with requirements. However, manufacturers use different methods to assay PRP content: a national control laboratory must establish and validate the relevant manufacturer methodology before using it to determine PRP content. An international study was organised by the World Health Organization (WHO), in collaboration with the Biological Standardisation Programme (BSP) of the Council of Europe/European Directorate for the Quality of Medicines & HealthCare (EDQM) and of the European Union Commission, to verify the suitability of a single method for determining PRP content in liquid pentavalent vaccines (DTwP-HepB-Hib) containing a whole-cell pertussis component. It consists of HCl hydrolysis followed by chromatographic separation and quantification of ribitol on a CarboPac MA1 column using high-performance anion exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD). The unconjugated, free, PRP is separated from the total PRP using C4 solid-phase extraction cartridges (SPE C4). Ten quality control laboratories performed two independent analyses applying the proposed analytical test protocol to five vaccine samples, including a vaccine lot with sub-potent PRP content and very high free PRP content. Both WHO PRP standard and ribitol reference standard were included as calibrating standards. A significant bias between WHO PRP standard and ribitol reference standard was observed. Study results showed that the proposed analytical method is, in principle, suitable for the intended use provided that a validation is performed as usually expected from quality control laboratories.
Assuntos
Cromatografia Líquida de Alta Pressão/normas , Cromatografia por Troca Iônica/normas , Vacina contra Difteria, Tétano e Coqueluche/análise , Vacinas Anti-Haemophilus/análise , Haemophilus influenzae tipo b/imunologia , Vacinas contra Hepatite B/análise , Polissacarídeos Bacterianos/análise , Polissacarídeos/análise , Cápsulas Bacterianas/imunologia , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Vacina contra Difteria, Tétano e Coqueluche/normas , Composição de Medicamentos , Europa (Continente) , Vacinas Anti-Haemophilus/imunologia , Vacinas Anti-Haemophilus/normas , Vacinas contra Hepatite B/imunologia , Vacinas contra Hepatite B/normas , Índia , Polissacarídeos/imunologia , Polissacarídeos/normas , Polissacarídeos Bacterianos/imunologia , Polissacarídeos Bacterianos/normas , Controle de Qualidade , Padrões de Referência , Reprodutibilidade dos Testes , República da CoreiaAssuntos
Carcinoma Hepatocelular/etiologia , Carcinoma Hepatocelular/prevenção & controle , Vacinas contra Hepatite B/normas , Hepatite B/complicações , Hepatite B/prevenção & controle , Neoplasias Hepáticas/etiologia , Neoplasias Hepáticas/prevenção & controle , Vacinas Anticâncer , Vacinas contra Hepatite B/administração & dosagem , HumanosRESUMO
The German Standing Committee on Vaccination (Ständige Impfkommission, STIKO) recommends vaccinating risk groups against hepatitis B and gives advice for postexposure prophylaxis. STIKO has recently revised this recommendation, focusing on: (i) classification of risk groups, (ii) duration of protection after primary immunization, and (iii) anti-HBs threshold that defines successful hepatitis B vaccination. Orientating literature reviews were performed for the first objective. Examples of population subgroups at increased risk were identified and classified into three indication groups. Systematic reviews on the duration of vaccine-induced protection identified one randomized controlled trial (RCT) and nine cohort studies. When applying the grading of recommendation, assessment, development, and evaluation (GRADE) methodology, evidence from RCTs was considered of very low quality regarding the question of whether hepatitis B can be prevented for 15 years after successful primary vaccination (anti-HBs ≥ 10 IU/l) with a vaccine efficacy of 96 % against chronic hepatitis, 89 % against HBsAg positivity, and 73 % against isolated anti-HBc positivity. However, seven cohort studies showed that no cases of clinical hepatitis B or HBsAg positivity occurred during a maximum follow-up period of 10 years in settings comparable to the situation in Germany when anti-HBs ≥ 10 IU/l was used to indicate vaccination success. Less than 1 % of vaccinated study participants had isolated anti-HBc positivity. GRADE assessment of two cohort studies revealed that evidence of very low quality exists that the use of anti-HBs ≥ 100 IU/l to measure vaccination success leads to a lower frequency of anti-HBc positivity during follow-up than the use of anti-HBs ≥ 10 IU/l. The recommendation was revised according to this evidence.
Assuntos
Medicina Baseada em Evidências , Vacinas contra Hepatite B/normas , Vacinas contra Hepatite B/uso terapêutico , Hepatite B/prevenção & controle , Profilaxia Pós-Exposição/normas , Vacinação/normas , Humanos , Resultado do TratamentoRESUMO
Despite a safe, effective vaccine, hepatitis B virus (HBV) vaccination coverage remains low among people who inject drugs (PWID). Characteristics of participants screened for a trial investigating the efficacy of financial incentives in increasing vaccination completion among PWID were examined to inform targeting of vaccination programs. Recruitment occurred at two health services in inner-city Sydney that target PWID. HBV status was confirmed via serological testing, and questionnaires elicited demographic, drug use, and HBV risk data. Multinomial logistic regression was utilized to determine variables independently associated with HBV status. Of 172 participants, 64% were susceptible, 17% exposed (HBV core antibody-positive), and 19% demonstrated evidence of prior vaccination (HBV surface antibody ≥ 10 mIU/ml). Compared with exposed participants, susceptible participants were significantly more likely to be aged less than 35 years and significantly less likely to be receiving current opioid substitution therapy (OST) and to test hepatitis C antibody-positive. In comparison to vaccinated participants, susceptible participants were significantly more likely to be male and significantly less likely to report daily or more frequent injecting, current OST, and prior awareness of HBV vaccine. HBV vaccination uptake could potentially be increased by targeting younger, less frequent injectors, particularly young men. In addition to expanding vaccination through OST, targeting "at risk" youth who are likely to have missed adolescent catch-up programs may be an important strategy to increase coverage. The lack of an association between incarceration and vaccination also suggests increasing vaccination uptake and completion in adult and juvenile correctional facilities may also be important.
Assuntos
Usuários de Drogas/estatística & dados numéricos , Vacinas contra Hepatite B/uso terapêutico , Hepatite B/etiologia , Abuso de Substâncias por Via Intravenosa/complicações , Adolescente , Adulto , Suscetibilidade a Doenças/sangue , Suscetibilidade a Doenças/epidemiologia , Feminino , Hepatite B/sangue , Hepatite B/prevenção & controle , Vacinas contra Hepatite B/normas , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , New South Wales/epidemiologia , Tratamento de Substituição de Opiáceos/estatística & dados numéricos , Ensaios Clínicos Controlados Aleatórios como Assunto , Sujeitos da Pesquisa , Testes Sorológicos , Distribuição por Sexo , Abuso de Substâncias por Via Intravenosa/epidemiologia , Abuso de Substâncias por Via Intravenosa/reabilitação , Adulto JovemAssuntos
Complicações do Diabetes/prevenção & controle , Diabetes Mellitus/microbiologia , Equipamentos e Provisões/microbiologia , Vacinas contra Hepatite B/normas , Hepatite B/prevenção & controle , Adulto , Complicações do Diabetes/sangue , Complicações do Diabetes/etiologia , Diabetes Mellitus/tratamento farmacológico , Desinfecção/métodos , Desinfecção/normas , Reutilização de Equipamento/normas , Hepatite B/transmissão , Vacinas contra Hepatite B/administração & dosagem , Humanos , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Fatores de Risco , Adulto JovemRESUMO
CB.Hep-1 monoclonal antibody (mAb) is used for a recombinant Hepatitis B vaccine manufacturing, which is included in a worldwide vaccination program against Hepatitis B disease. The use of this mAb as immunoligand has been addressed into one of the most efficient steps of active pharmaceutical ingredient purification process. Regarding this, Quality Risk Management (QRM) provides an excellent framework for the risk management use in pharmaceutical manufacturing and quality decision-making applications. Consequently, this study sought applying a prospective risk analysis methodology Failure Mode Effects Analysis (FMEA) as QRM tool for analyzing different CB.Hep-1 mAb manufacturing technologies. As main conclusions FMEA was successfully used to assess risks associated with potential problems in CB.Hep-1 mAb manufacturing processes. The severity and occurrence of risks analysis evidenced that the percentage of very high severe risks ranged 31.0-38.7% of all risks and the huge majority of risks have a very low occurrence level (61.9-83.3%) in all assessed technologies. Finally, additive Risk Priority Number, was descending ordered as follow: transgenic plants (2636), ascites (2577), transgenic animals (2046) and hollow fiber bioreactors (1654), which also corroborated that in vitro technology, should be the technology of choice for CB.Hep-1 mAb manufacturing in terms of risks and mAb molecule quality.
Assuntos
Anticorpos Monoclonais/biossíntese , Vacinas contra Hepatite B/biossíntese , Animais , Animais Geneticamente Modificados , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais Murinos/biossíntese , Anticorpos Monoclonais Murinos/imunologia , Biotecnologia/métodos , Cromatografia de Afinidade , Anticorpos Anti-Hepatite B/biossíntese , Anticorpos Anti-Hepatite B/imunologia , Vacinas contra Hepatite B/imunologia , Vacinas contra Hepatite B/isolamento & purificação , Vacinas contra Hepatite B/normas , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Plantas Geneticamente Modificadas , Gestão de RiscosAssuntos
Vacinas contra a AIDS/normas , Infecções por HIV/prevenção & controle , Licenciamento , Vacinas contra a AIDS/economia , Vacinas contra a AIDS/imunologia , Vacinas contra a AIDS/provisão & distribuição , Ensaios Clínicos como Assunto , Países em Desenvolvimento , Variação Genética , Antígenos HIV/genética , Antígenos HIV/imunologia , Infecções por HIV/imunologia , HIV-1/imunologia , HIV-1/patogenicidade , Vacinas contra Hepatite B/economia , Vacinas contra Hepatite B/imunologia , Vacinas contra Hepatite B/normas , Humanos , Vacinas contra Influenza/imunologia , Vacinas contra Influenza/normas , Vacinas contra Papillomavirus/economia , Vacinas contra Papillomavirus/imunologia , Tailândia , VacinaçãoRESUMO
A highly sensitive sandwich enzyme-linked immunosorbent assay (ELISA) for quantifying BSA was established, based on two mAbs that recognize different epitopes on a BSA molecule. Our ELISA system was used to detect BSA concentrations in several vaccines, such as the MMR (measles, mumps and rubella) vaccine, hepatitis A vaccine, and hepatitis B vaccine. Moreover, we compared the mAb ELISA and the present pAb ELISA by detecting BSA standards and bovine serum samples. The results showed that our ELISA system was in good accordance with the pAb ELISA system. A pair of mAbs (FMU-BSA NO.6 and FMU-BSA NO.11) from 11 murine hybridomas secreting BSA-specific mAbs was selected for the development of the sandwich ELISA. The detection limit of this quantitative assay reaches 0.38 µg/L, which is 10-fold more sensitive than those previously reported. The quantitative range of BSA concentration is from 0.5 to 40 µg/L, which is comparable to the currently used polyclonal antibody (pAb) ELISA. Intra-assay and inter-assay coefficient variations are both lower than 10% at the three concentrations used (10, 20, and 40 µg/L). Thus, the mAb sandwich ELISA developed herein may provide a stable, precise, and highly sensitive method for quantifying BSA, which is very useful in the quality control of some vaccines.
Assuntos
Anticorpos Monoclonais/imunologia , Soroalbumina Bovina/análise , Vacinas Virais/química , Vacinas Virais/normas , Animais , Bovinos , Ensaio de Imunoadsorção Enzimática/métodos , Vacinas contra Hepatite A/química , Vacinas contra Hepatite A/normas , Vacinas contra Hepatite B/química , Vacinas contra Hepatite B/normas , Hibridomas , Vacina contra Sarampo-Caxumba-Rubéola/química , Vacina contra Sarampo-Caxumba-Rubéola/normas , Camundongos , Controle de Qualidade , Sensibilidade e Especificidade , Soroalbumina Bovina/imunologiaRESUMO
In hepatitis B virus (HBV) infection-preventing programs, serum or plasma levels of antibody to hepatitis B surface antigen (anti-HBs) are important to determine whether individuals are protective or not. We compared anti-HBs responses using passive hemagglutination assay (Mycell) and chemiluminescent immunoassay (Architect) among four recipient groups of HB vaccines, Meinyu, HBY, Bimmugen and Heptavax II, that have been approved in Japan. Overall, in a total of 1875 vaccinees Mycell results showed recipient groups of Meinyu and HBY acquired higher anti-HBs levels than those of Bimmugen and Heptavax II. Comparison of anti-HBs responses by both Mycell and Architect in recipient groups of Meinyu (n=150), HBY (n=218), Bimmugen (n=260), and Heptavax II (n=47) demonstrated the order of vaccinees' responses, such as geometric mean titers, ratios of acquiring high antibody levels (Mycell titers over 1024, Architect measurements over 1000 mIU/mL), and ratios of having unsuccessful antibody responses (Mycell titers under 8, Architect measurements under 10 mIU/mL), were somewhat different between the two assays. Comparison of Architect measurements at given Mycell titers revealed Bimmugen-recipients showed significantly lower values than HBY- or Heptavax II-recipients. Around critical protective levels, 5 of 22 Bimmugen-recipients with Mycell titers 16 or 32 showed Architect measurements under 10 mIU/mL, while 8 of 11 Heptavax II-recipients with Mycell titers below 8 demonstrated Architect measurements over 10 mIU/mL. Thus, discrepancies in anti-HBs evaluation between Mycell and Architect seemed to partly depend on administered vaccines. These results indicate anti-HBs concentration should be evaluated carefully so that we could completely prevent HBV infection.
Assuntos
Formação de Anticorpos/fisiologia , Testes de Hemaglutinação , Antígenos de Superfície da Hepatite B/imunologia , Vacinas contra Hepatite B/normas , Medições Luminescentes , Vacinas contra Hepatite B/imunologia , Humanos , JapãoRESUMO
Vaccines containing aluminum salt adjuvants are prone to inactivation following exposure to freeze-thaw stress. Many are also prone to inactivation by heat. Thus, for maximum potency, these vaccines must be maintained at temperatures between 2 degrees C and 8 degrees C which requires the use of the cold chain. Nevertheless, the cold chain is not infallible. Vaccines are subject to freezing during both transport and storage, and frozen vaccines are discarded (under the best circumstances) or inadvertently administered despite potentially reduced potency. Here we describe an approach to minimize our reliance on the proper implementation of the cold chain to protect vaccines from freeze-thaw inactivation. By including PEG 300, propylene glycol, or glycerol in a hepatitis B vaccine, particle agglomeration, changes in the fluorescence emission spectrum--indicative of antigen tertiary structural changes--and losses of in vitro and in vivo indicators of potency were prevented following multiple exposures to -20 degrees C. The effect of propylene glycol was examined in more detail and revealed that even at concentrations too low to prevent freezing at -10 degrees C, -20 degrees C, and -80 degrees C, damage to the vaccine could be prevented. A pilot study using two commercially available diphtheria, tetanus toxoid, and acellular pertussis (DTaP) vaccines suggested that the same stabilizers might protect these vaccines from freeze-thaw agglomeration as well. It remains to be determined if preventing agglomeration of DTaP vaccines preserves their antigenic activity following freeze-thaw events.
Assuntos
Compostos de Alumínio , Estabilidade de Medicamentos , Armazenamento de Medicamentos , Congelamento , Vacinas/química , Vacinas/normas , Adjuvantes Farmacêuticos/química , Animais , Química Farmacêutica , Glicerol/química , Anticorpos Anti-Hepatite B/sangue , Vacinas contra Hepatite B/química , Vacinas contra Hepatite B/normas , Camundongos , Camundongos Endogâmicos BALB C , Propilenoglicol/químicaRESUMO
OBJECTIVE: To evaluate the effectiveness of a recombinant hepatitis B vaccine used in endemic areas of Colombia, as well as risk factors associated with hepatitis B virus (HBV) infection and carriage after vaccine introduction. METHODS: A cross-sectional study was carried out in urban and rural areas of the Colombian Amazon, a highly endemic area for hepatitis B infection. Children under 12 years of age and their mothers were selected for the study using one-stage cluster sampling (N=2145) and were examined for HBV serological markers and antibodies against surface antigen (anti-HBs). RESULTS: There has been a reduction of 60-75% in the prevalence of HBV infection and hepatitis B surface antigen (HBsAg) carriage since HBV vaccination was introduced. Receiving the first dose of HBV vaccine at more than two months after birth was one of the factors associated with HBV carrier status. Maternal HBV infection was also associated with infection in the child. CONCLUSIONS: The recombinant Cuban hepatitis B vaccine has contributed to the reduction of the infection in this highly endemic area, though further efforts are required to improve timely vaccination for children at high risk.
Assuntos
Anticorpos Anti-Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Vacinas contra Hepatite B/administração & dosagem , Vírus da Hepatite B/imunologia , Hepatite B/epidemiologia , Adolescente , Adulto , Criança , Pré-Escolar , Colômbia/epidemiologia , Estudos Transversais , Feminino , Hepatite B/sangue , Hepatite B/prevenção & controle , Vacinas contra Hepatite B/imunologia , Vacinas contra Hepatite B/normas , Humanos , Esquemas de Imunização , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , População Rural , População Urbana , Vacinas Sintéticas/administração & dosagem , Vacinas Sintéticas/normasRESUMO
BACKGROUND: The goal of this study was to conduct an accelerated vaccination program and to determine its efficacy in patients susceptible to hepatitis B virus (HBV) receiving chemotherapy because of their hematologic malignancies. METHODS: Over a one-year period, a total of 327 patients who were diagnosed as having a hematologic malignancy were serologically analyzed in terms of HBV infection. Of those found to be susceptible to HBV infection, a total of 42 patients consisting of 16 females and 26 males were enrolled in the accelerated vaccination program. All the patients were administered a 20-microg yeast-derived recombinant hepatitis B vaccine on days 0, 14, and 28. Anti-HBs titers above 10IU/l at 1 and 3 months after the final dose were accepted as protective. RESULTS: A total of 146 (44.6%) patients were susceptible to HBV, while 13 (4.0%) were carriers, 28 (8.6%) were vaccinated, and 113 (34.5%) had had a previous HBV infection. A total of 42 patients (16 females and 26 males, mean age 34.5+/-10.9 years) were enrolled in the vaccination program. Overall, 23.8% (10/42) of the patients in the program had developed anti-HBs at one month after the last vaccination. CONCLUSIONS: Poor results obtained by different vaccination programs suggest the need for alternative strategies to prevent the disease.
Assuntos
Neoplasias Hematológicas/complicações , Vacinas contra Hepatite B/administração & dosagem , Hepatite B/prevenção & controle , Vacinação/normas , Adolescente , Adulto , Distribuição por Idade , Idoso , Antineoplásicos/uso terapêutico , Feminino , Neoplasias Hematológicas/tratamento farmacológico , Hepatite B/imunologia , Anticorpos Anti-Hepatite B/sangue , Antígenos da Hepatite B/sangue , Vacinas contra Hepatite B/normas , Humanos , Esquemas de Imunização , Técnicas Imunoenzimáticas , Masculino , Pessoa de Meia-Idade , Distribuição por Sexo , Vacinação/métodosRESUMO
The scientific and regulatory issues that are associated with the possible introduction of 'follow-on' versions of protein drug products are the topic of considerable debate at present. Because of the differences between protein drug products and small-molecule drugs, the development of follow-on versions of protein products presents more complex scientific challenges than those presented by the development of generic versions of small-molecule drugs. Here, with a view to illustrating the Food and Drug Administration's (FDA's) scientific reasoning and experience in this area, we discuss past examples of the FDA's actions involving the evaluation of various types of follow-on and second-generation protein products and within-product manufacturing changes. The FDA believes its evaluation of the safety and effectiveness of follow-on protein products will evolve as scientific and technological advances in product characterization and manufacturing continue to reduce some of the complexity and uncertainty that are inherent in the manufacturing of protein products.
Assuntos
Aprovação de Drogas , Proteínas/normas , Proteínas Recombinantes/normas , Albuminas/normas , Alérgenos , Calcitonina/normas , Epoetina alfa , Eritropoetina/normas , Vacinas contra Hepatite B/normas , Hialuronoglucosaminidase/normas , Estados Unidos , United States Food and Drug AdministrationRESUMO
The seeding and working banks of a 4647-cell culture have been created. The 4647-cell culture in these banks has a high proliferative activity, as well as the morphology, typical of this line, and the karyotype and the enzymogram, which are characteristic for the cells of an African talapoin (Cercopithecus aethiops). The culture is not contaminated with bacteria, fungi, Mycoplasma, and viruses, including oncoviruses. The deposited 4647 cells have high viral productive properties for the accumulation of the recombinant virus strain b7,5S2-S vaccine and keep the stability of all biological properties during a long-term cultivation. The continuous 4647 cell line was tested at the L. A. Tarasevich State Institute of SK. The seeding and working banks of 4647-cell culture at passages 108 and 128 are recommended as a substrate for cultivation of the strain b7,5S2-S vaccinia, used to prepare a bivaccine against smallpox and hepatitis B.